Transplantation for the Complex Patient with Hepatitis C and End Stage Renal Disease: A Review by Ortiz, Jorge et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
17 
Transplantation for the Complex 
Patient with Hepatitis C and End 
Stage Renal Disease: A Review 
Jorge Ortiz, Jason Andre and Kamran Khanmoradi Victor Araya 
Albert Einstein Medical Center, Philadelphia PA 
USA 
1. Introduction 
Hepatitis C (HCV) and End Stage Renal Disease (ESRD) are two major health issues 
affecting millions worldwide. The diagnosis of HCV in the dialysis patient has significant 
prognostic indications and specific interventions are necessary in order to evaluate the 
extent of liver disease and the feasibility of medical treatment or the need for organ 
replacement therapy. For the transplant candidate, unique issues with respect to 
immunosuppressive agents and the appropriate use of HCV positive donors may be 
particularly vexing. Prior reviews have focused on issues classically limited to nephrology 
or hepatology, this update will address transplantation issues as well. 
2. Epidemiology 
The Hepatitis C virus (HCV) is a member of the Flaviviridae family. Approximately 150 
million people are infected by this single stranded RNA virus, 5 million of whom live in the 
United States. It is estimated that 85% of patients will develop chronic infection, which is 
defined as the presence of HCV RNA for six months after presumed onset. Subsequent 
spontaneous clearing of the virus is rare. Approximately 10-30% will develop cirrhosis. In 
the renal dialysis population, the incidence of de novo infection is 3-7% per year. The 
prevalence ranges from 10-20% and may be underestimated due to cases of low viral 
load.1,2,3 
Factors associated with virus acquisition in this patient population include the number of 
blood units transfused (which has decreased with the advent of erythropoietin alpha and 
blood bank screening), the length of dialysis therapy and the type of renal replacement 
therapy. Patients on hemodialysis are at higher risk compared to those on peritoneal 
dialysis.4 There are at least six genotypes and many subtypes. HCV accounts for 30-50% of 
liver transplantation procedures performed and is also associated with many extra hepatic 
manifestations,5 (Table 1) most importantly diabetes. The mechanisms underlying the 
diabetogenicity of HCV likely involve insulin resistance, diminished hepatic glucose uptake 
and the directly injurious effect of the virus on beta cells of the pancreas.6 In the kidney, 
HCV is strongly associated with membranoproliferative glomerulonephritis (MPGN), 
membranous glomerulonephritis, focal segmental glomerulosclerosis, mesangial 
proliferative glomerulonephritis7 and albuminuria.8 Clinically silent immune complex 
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glomerulonephritis was commonly seen in biopsies of patients with end stage HCV liver 
disease undergoing liver transplantation.9 
 
Antiphospholipid syndrome 
Aplastic Anemia 
Autoimmune hemolytic anemia 
Autoimmune thyroiditis 
Chronic fatigue syndrome 
Behcet’s Syndrome 
Carotid atherosclerosis 
CRST syndrome 
Dermatomyositis 
Diabetes 
Fibromyalgia 
Guillain-Barré syndrome 
Hypertrophic cardiomyopathy 
Hypocholesterolemia 
Idiopathic pulmonary fibrosis 
Idiopathic thrombocytopenic purpura 
IgA deficiency 
Lichen planus 
MALToma 
Mooren corneal ulcers 
Multiple myeloma 
Non-Hodgkins lymphoma 
Neurocognitive impairment 
Pancreatitis Polyarteritis nodosa 
Polymyositis Porphyria cutanea tarda 
Rheumatoid arthritis 
Sialadenitis 
Sjogren’s syndrome 
Systemic lupus erythematosis 
Uveitis 
Waldenstrom’s macroglobuminemia 
 
Table 1. Extrahepatic disease manifestations with HCV infection 
3. Evaluation for treatment and kidney transplantation 
Evaluation of the potential kidney transplant recipient with HCV involves a careful history 
and physical examination. Patients with encephalopathy, variceal bleeding, ascites and 
muscle wasting have significant risk of continued deterioration and should be considered 
for liver (and kidney) transplantation. The presence of hepatocellular carcinoma within the 
Milan or UCSF criteria10 should also be considered an indication for combined liver and 
kidney transplantation. 
False positives (and negatives (0.23%)) are not uncommonly seen with the current 
generation of ELISA blood tests and therefore a confirmatory PCR should be ordered11. The 
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mean time from detection of HCV RNA to the appearance of antibody may be as long as six 
months12. Nevertheless, screening with PCR is not recommended. A negative PCR in a 
previously positive patient should be repeated because frequent variations in the viral load 
can be seen. The genotype of the virus may determine its susceptibility to interferon 
treatment. However, early studies in patients with renal replacement therapy failed to 
demonstrate that HCV genotype is a factor in interferon responsiveness13. Additionally, 
HCV genotype does not seem to influence survival in renal transplant recipients14.  
4. Biopsy 
Liver function tests are not sensitive enough to determine whether there is significant 
inflammation or even cirrhosis15. Liver biopsies are therefore indicated in all HCV positive 
candidates being considered for kidney transplantation and possible treatment. Studies 
indicate that advanced fibrosis is a common finding despite normal aminotransferase 
levels16. Histologic features of chronic hepatitis will be seen in 100% of ESRD patients with 
HCV. 60-80% of patients will have significant fibrosis and 10-12% will have cirrhosis17. 
Established cirrhosis was found to be the most important predictor of death after renal 
transplantation and is considered a relative contraindication to isolated renal 
transplantation18. If the liver biopsy shows cirrhosis mandatory screening for hepatocellular 
carcinoma must be instituted19. 
Regarding the biopsy technique, obtaining tissue via the transjugular route may be safer 
than the percutaneous method especially if the patient has ascites, disorders of the 
coagulation system or undergoes peritoneal dialysis. An additional advantage of the 
transjugular approach is the determination of portal pressure gradients which may help to 
diagnose sub clinical portal hypertension. Radiologic imaging or upper endoscopy (another 
important screening tool) may demonstrate obvious cirrhosis and varices perhaps obviating 
the need for this particular intervention. In the absence of cirrhosis, biopsies should be 
performed at five year intervals. Surrogate serum markers for fibrosis and cirrhosis have 
been investigated but are not yet the standard of care20. 
5. Hepatocellular carcinoma 
The incidence of hepatocellular carcinoma (HCC) is increasing in the general population21 
and is higher in patients with ESRD. The prognosis is also worse for patients with ESRD22. 
Screening is crucial as prognosis after the onset of symptoms is dismal while patients with 
small expeditiously treated lesions reap a significant survival advantage. The yearly risk of 
HCC in patients with HCV is highest in those with established cirrhosis (about 2-8% per 
year). HCV infected patients who do not have cirrhosis have a lower risk of developing 
HCC. Based on current knowledge all patients with HCV and cirrhosis should undergo 
surveillance. This should entail a radiologic exam (CT scan, MRI or ultrasound) and alpha 
fetoprotein monitoring. These screens should be performed (in cirrhotics) at 6-12 month 
intervals. If HCC is found, metastatic workup includes bone scans and chest CT scans. 
Surgical resection can be safely performed for patients with ESRD and preserved liver 
function23. For patients with decompensated cirrhosis and small solitary HCC or early 
multifocal disease (up to three lesions, total tumor burden less than 6.5cm) the best option is 
liver (and kidney) transplantation24. Other modalities used to treat HCC include 
chemoembolization, alcohol infusion, radiofrequency ablation,Y-90, and acetic acid infusion. 
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Systemic chemotherapy is not associated with improvements in patient survival. Sorafenib 
(Nexavar) may be associated with survival improvements in untransplantable patients. 
6. Anti viral therapy 
Antiviral therapy before transplantation with the objective of eradicating the virus is the 
current standard of care. Secondary benefits may include the prevention of hepatic 
decompensation and hepatocellular carcinoma. In dialysis patients, the only recommended 
treatment is Alpha Interferon monotherapy. The average virological response is 40% and is 
independent of genotype. Interferon therapy interruption, seen in up to 60% of patients, is 
due to side effects. The most common of which are flu like symptoms, neurologic symptoms 
and gastrointestinal symptoms. Sustained viral response (SVR) may be durable (22 months 
average) post transplantation in those patients successfully treated before surgery. Of the 
sixteen patients studied in one report, HCV viral counts remained negative in all.25 
Immunosuppressive issues remain troublesome in this complex patient population. Others 
have also indicated that successfully treated dialysis patients may have an improved graft 
survival and lower incidence of HCV related kidney disease26 and new onset post transplant 
diabetes. 
The higher rate of SVR after interferon therapy may result from higher levels of interferon in 
patients with renal failure. The dose of interferon is 3 million units one to three times a 
week. Pegylated interferons, although commonly used, are not yet recommended. From a 
pharmacokinetic standpoint dose adjustments would probably be unnecessary in patients 
with renal impairment27. Absorption may vary with a patient on dialysis28. One study 
reported 87.5% viral clearance in 8 patients after 12 weeks of therapy. All of the 6 patients 
who completed 48 weeks of therapy achieved a biochemical response28. In another report, 
two of six genotype 1 patients completed a 24 week course of Pegylated Interferon and 
achieved a SVR30. The appropriate dose of Pegylated Interferon Alpha-2 is probably 135 
micrograms a week, this gives similar serum levels as 180 micrograms per week in patients 
with preserved renal function. Pegylated Interferon Alpha-2 should probably be dosed 
between 0.5-1.0 micrograms/kg (as opposed to 1.0-1.5 ug/kg)31. 
Ribavirin is contraindicated, alone and with interferon, because of the hemolytic anemia 
associated with it. However, some groups have shown that it can be used in combination 
with interferon at reduced dosages with plasma monitoring and erythropoietin and iron 
supplementation32. These studies did not prove that ribavirin in low doses, in this 
population, improved response rates. It is very important to note that if hemolysis results 
in anemia that necessitates blood transfusion, the patient may be rendered 
untransplantable because of increased immune reactivity. Amantadine has not proven 
beneficial.  
In kidney transplant recipients, interferon treatment is contraindicated because of the 
increased risk of acute cellular and antibody meditated rejection33. An exception is the 
patient with fibrosing cholestatic hepatitis (FCH). FCH is characterized by cholestasis with 
only mild to moderate elevation of transaminases and a rapid deterioration in liver 
function34. Some investigators believe that after combined liver and kidney transplantation, 
the liver protects the kidney from rejection and interferon can therefore safely be 
administered. 
Ribavirin monotherapy may improve serum aminotransferases and proteinuria, but its 
effect on liver histology is controversial. Chronic hemolysis may prevent its safe use. Some 
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have recommended that ribavirin be dose adjusted for those renal transplant recipients with 
HCV who have developed significant proteinuria35. 
7. Prognosis 
HCV infection in renal failure patients is usually asymptomatic. The virus seems to have a 
lower impact on the liver histology of dialysis patients than on the histology of the HCV-
positive immunocompetent patients with normal renal function36. It would appear that 
histological progression of liver injury after transplantation is minimal in HCV positive 
kidney recipients. In fact, fibrosis might regress in some patients37. Nevertheless, it is a 
negative prognostic indicator for survival on dialysis and after kidney transplantation. HCV 
may intensify oxidative stress in patients with uremia, leading to cardiovascular 
compromise38. Diabetes and cardiovascular disease were statistically significantly associated 
with patient death (while on dialysis) in one study39. Those patients with cirrhosis have a 
35% higher death rate than noncirrhotic counterparts.40,41 In another report, HCC was a 
statistically significantly more common cause of death in HCV positive dialysis patients42. 
Overall survival in these patients is improved after kidney transplantation compared to 
remaining on dialysis, despite the theoretical risk of accelerating virus replication with 
immunosuppression43, but worse than HCV negative counterparts. This might be related to 
an increased risk of cardiovascular disease, posttransplant diabetes mellitus, sepsis 44,45,46, 
and rejection47. Thrombotic microangiopathy, MPGN and proteinuria are also associated 
with HCV infection and may result in lower rates of patient and graft survival48. The most 
common cause of proteinuria post transplant is still chronic allograft nephropathy, and a 
biopsy is crucial for the diagnosis49. All cause hospitalizations are significantly higher in 
HCV positive kidney recipients compared to HCV negative ones. HCV positive kidney 
transplant recipients are more likely to be African American, male, older, and have a higher 
rate of alcohol abuse, experience extended time on dialysis, malnutrition (as measured by 
serum albumin) and prior transplantation. Those patients with concomitant hepatitis B 
infection do particularly poorly in terms of patient and graft survival50. As do patients with 
HIV co-infection51. 
8. HCV and Tacrolimus 
As stated, HCV infection is associated with pre transplant and de novo post transplant 
diabetes. This is seen more commonly with Tacrolimus compared to Cyclosporine. 
Nevertheless, the U.S. FK506 multicenter trial demonstrated higher patient survival in those 
HCV positive patients who received Tacrolimus compared to Cyclosporine. According to a 
recent query of the UNOS database (Tables 2-3), 1,3,5 year graft survival for HCV positive 
recipients of HCV negative organs was 89.7%, 76.7% and 61.6% for those patients treated 
with cyclosporine. 1,3,5 year graft survival with Tacrolimus immunosuppression was 92.2%, 
80.6% and 63.3%. If the donor were HCV positive, 1,3,5 year graft survival for HCV positive 
recipients was 92.7%, 76% and 56.3% for cyclosporine treated recipients and 89.6%, 74.6% 
and 52.5% for Tacrolimus treated patients. Patient survival at 1,3, and 5 years for HCV 
negative donor organs was 94.8%, 88.8% and 80.5% with cyclosporine 95.6%, 89.4% and 
79.7% with Tacrolimus. If the donor were HCV positive, patient survival at 1,3 and 5 years 
was 98%, 91.1% and 82% for cyclosporine and 93.9%, 87% and 75.8% for Tacrolimus.52 The 
mechanisms behind diminished graft and patient survival with HCV positive donors and 
Tacrolimus immunosuppression are not entirely clear.  
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Table 2. Graft Survival by Donor HCV status and Main Maintenance Immunosuppression 
Agent 
 
 
 
Table 3. Patient Survival By Donor HCV Status and Main Maintenance Immunosuppression 
Agent 
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9. Mycophenolate, steroids and induction agents 
Another risk factor for diabetes, and a multitude of other complications, is prolonged 
steroid usage. Early rapid withdrawal has been reported to be safe (at least in the short 
term) compared with a historic control group53. The use of mycophenolate mofetil is 
associated with improved survival (at least with HCV positive donors) due to fewer 
infectious deaths54. Patients induced with OKT3 or anti-lymphocyte globulin have 
experienced inferior survivals54. The UNOS database was queried for 1,3 and 5 year patient 
and graft survival for HCV recipients of donor positive and donor negative organs stratified 
by induction agent (see Table 4). Definitive conclusions pertaining to the best induction 
agent for the ESRD patient with HCV can not be made until randomized prospective trials 
are performed. 
 
 
Table 4. Graft Survival by Donor HCV Status and Induction Agent 
10. HCV positive donors 
The organ donor shortage has compelled centers to transplant kidneys from donors who test 
positive for HCV. The prevalence and utilization of HCV positive organ donor referrals has 
increased in the United States. The prevalence of HCV is several fold higher in deceased 
donors compared to healthy living blood donors. Almost 20% of anti HCV positive donors 
will be RNA negative56. The utilization of HCV positive kidneys for HCV negative 
recipients is contraindicated57, 58. 
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Surprisingly, Bucci et al demonstrated that 34.1% of HCV positive donor kidneys were 
allocated to HCV negative recipients in the United States in 200059. The use of donor positive 
kidneys for HCV positive recipients is associated with greater long term mortality compared 
to virus negative kdneys. Although HCV positive recipients more frequently develop new 
onset diabetes mellitus (NODM) compared to negative controls, the risk is heightened with 
HCV positive donors60. Nevertheless, in comparison to staying on the waitlist, 
transplantation with donor virus positive kidneys is associated with increased survival in 
HCV positive recipients61. There is no definitive proof that conversion of genotype after 
transplantation portends a bad prognosis. Nevertheless, one case reported did implicate a 
genotypic mismatched kidney transplant in the exacerbation of hepatic dysfunction62. Any 
possible adverse effect of super infection with a different genotype is believed to be 
outweighed by the beneficial effect of decreased time on dialysis63. 
11. Summary 
The patient with HCV and ESRD is very complex. All positive antibody screens should be 
confirmed with PCR. The standard workup should include a search for clinical signs of 
hepatic decompensation and a liver biopsy. The biopsy, if it does not show cirrhosis, should 
be repeated at 5 year intervals. Patients should be treated with interferon if at all possible in 
order to minimize long term hepatologic complications and to improve outcomes after 
kidney transplantation. The formulation of interferon and the exact dosing remain a matter 
of debate. Ribavirin should probably be used only with close follow up and in a setting of a 
trial. After transplantation, interferon is contraindicated.  
Although HCV is a negative prognostic indicator, those patients with HCV are better served 
transplanted compared to remaining on the waitlist. HCV positive organ donors are also a 
negative prognostic indicator but nonetheless may confer a significant survival advantage 
due to the associated decrease in the wait time for a deceased organ. Decompensated 
cirrhosis is an indication for combined liver and kidney transplantation.  At this time well 
compensated cirrhotics are not considered candidates for single or dual organ transplants, 
although many centers perform both. Mycophenolate mofetil and steroid freedom have 
been shown to be safe in this patient population. The results with various calcineurin 
inhibitors and induction agents have been reviewed. Until randomized perspective trials are 
performed, the choice of which medication to employ is center specific and experience 
driven. 
12. Conclusion 
HCV will remain a major health issue for decades to come. Appropriate communication 
between disciplines is mandatory in order to ensure excellent patient outcomes. 
Randomized trials and multi-disciplinary meetings are indicated. 
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